PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING EYE DISEASES, CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TISSUE-PENETRATING PEPTIDE AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PREPARATION ARE FUSED
Seong Beom KIM,Hyei Yoon JUNG,Seok Woo YANG,Hyuk Sang KWON,Jae-Hoon KANG
申请号：
US15720016
公开号：
US20180133288A1
申请日:
2017.09.29
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial growth factor (anti-VEGF) preparation are fused. More particularly, the present invention relates to: a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused； a method for prepraring an anti-VEGF preparation, which overcomes resistance and has an improved efficacy, the method comprising the steps of transforming a host cell with a recombinant vector comprising a nucleic acid sequence encoding a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused, culturing the cell, and recovering a fusion protein from the cell； a method for treating eye diseases, comprising administering an effective dose of the fusion protein according to the present invention to a subject in need thereof； and use of the fusion protein according to the present invention for preparing an agent for treating eye diseases. Compared to conventional anti-VEGF preparations, the composition according to the present invention is considered to have an improved efficacy and be able to be used for treating patients having drug resistance, by inhibiting various growth factors related to new blood vessels, besides VEGF, and by decreasing pericyte coverage. In addition, since drug delivery ability into the choroid tissue is improved when performing an intraocular injection, the composition can be developed as eye drops by reducing an administered dosage or extending an administration cycle, and by improving ocular penetrability.
